Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to evaluate the safety, tolerability and pharmacokinetics of single-and multiple-dose IMM0306 for refractory or relapsed CD20-positive (CD20+) B-cell non-Hodgkin's lymphoma

Next Previous
Trial Profile

A clinical study to evaluate the safety, tolerability and pharmacokinetics of single-and multiple-dose IMM0306 for refractory or relapsed CD20-positive (CD20+) B-cell non-Hodgkin's lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amulirafusp alfa (Primary)
  • Indications B-cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Pharmacokinetics

Most Recent Events

  • 06 Jun 2023 Preliminary (n=42; As of the data cut-off date on Dec 15th, 2022) results assessing the safety, pharmacokinetics, pharmacodynamics, and efficacy results of the dose escalation stage in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 13 Dec 2022 Preliminary Results for safety and efficacy (As of Jul 13th, 2022, n=26), presented at the 64th American Society of Hematology Annual Meeting and Exposition
  • 09 Nov 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top